Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Collegium Pharmaceutical (COLL) Income from Continuing Operations (2016 - 2025)

Collegium Pharmaceutical (COLL) has 10 years of Income from Continuing Operations data on record, last reported at 45030000.0 in Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 259.21% year-over-year to 45030000.0; the TTM value through Dec 2025 reached 96684000.0, up 23.8%, while the annual FY2025 figure was 108613000.0, 15.75% up from the prior year.
  • Income from Continuing Operations reached 45030000.0 in Q4 2025 per COLL's latest filing, up from 31507000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 72843000.0 in Q2 2021 and bottomed at 25034000.0 in Q4 2021.
  • Average Income from Continuing Operations over 5 years is 14211150.0, with a median of 12771500.0 recorded in 2023.
  • The widest YoY moves for Income from Continuing Operations: up 7577.45% in 2021, down 459.79% in 2021.
  • A 5-year view of Income from Continuing Operations shows it stood at 25034000.0 in 2021, then skyrocketed by 71.24% to 7199000.0 in 2022, then soared by 748.84% to 46710000.0 in 2023, then crashed by 73.16% to 12536000.0 in 2024, then skyrocketed by 259.21% to 45030000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Income from Continuing Operations were 45030000.0 in Q4 2025, 31507000.0 in Q3 2025, and 17025000.0 in Q2 2025.